WHAT IS
TACE THERAPY?
TACE β transarterial chemoembolisation β exploits the unique dual blood supply of the liver to deliver concentrated chemotherapy directly into liver tumours while cutting off their arterial blood supply, combining direct cytotoxicity with ischaemic cell death in a single catheter-based procedure.
analyticsAt a Glance
- check_circleTACE is the BCLC-recommended standard of care for intermediate-stage (BCLC B) hepatocellular carcinoma
- check_circleTwo main techniques: conventional TACE (cTACE) with Lipiodol and drug-eluting beads TACE (DEB-TACE)
- check_circlePerformed by an interventional radiologist under X-ray guidance β no surgery, no general anaesthesia required in most cases
- check_circleWidely available at hepatology and interventional oncology centres in China and India via CancerFax
What Is TACE and How Does It Work?
The liver has a unique dual blood supply: most normal liver tissue is fed by the portal vein, while liver tumours β including HCC β derive 80β90% of their blood supply from the hepatic artery. TACE exploits this difference by threading a microcatheter through the femoral artery, up through the aorta, and into the hepatic artery branch supplying the tumour β delivering chemotherapy directly into the tumour's blood supply before embolising (blocking) the vessel.
βTACE turns the tumour's own vascularity against it β using the same blood supply that feeds the cancer to deliver the drug directly to it, then cutting off that supply to trap the drug inside and starve the tumour simultaneously.β
The Two Mechanisms of TACE
TACE works through two simultaneous mechanisms: (1) Direct cytotoxicity β high-concentration chemotherapy (typically doxorubicin, cisplatin, or mitomycin C) delivered directly into the tumour achieves local drug concentrations 10β75Γ higher than systemic IV delivery; (2) Ischaemic necrosis β embolisation of the feeding artery cuts off oxygen and nutrients, causing tumour hypoxia and cell death through a mechanism independent of chemotherapy.
Why Normal Liver Is Largely Spared
Because TACE targets the hepatic artery β which mainly feeds tumours β the portal vein continues to supply normal hepatocytes throughout the procedure. This selective delivery protects surrounding liver parenchyma from both the chemotherapy and the embolic material, allowing repeated TACE sessions over months to years without the cumulative hepatic toxicity that would occur with systemic chemotherapy.
What Happens During a TACE Procedure
TACE is performed in an interventional radiology suite under X-ray (fluoroscopic) guidance, typically under conscious sedation or light general anaesthesia.
- 1
Pre-Procedure Preparation
The patient is fasted for 4β6 hours. IV access is established, blood tests confirm adequate liver function and clotting. Contrast allergy and renal function are reviewed. Antiemetics and antibiotics are prescribed per protocol.
- 2
Femoral Artery Access
The interventional radiologist inserts a thin catheter through the femoral artery in the groin (or radial artery in the wrist). This is performed under local anaesthesia β a brief sting followed by pressure sensation.
- 3
Hepatic Arteriogram
A contrast arteriogram maps the hepatic arterial anatomy, identifies the tumour's feeding vessels, and confirms the catheter position before any treatment is delivered.
- 4
Superselective Catheterisation
A microcatheter is advanced through the hepatic artery into the segmental or subsegmental artery supplying the target tumour β as selectively as possible to minimise exposure of normal liver.
- 5
Drug and Embolic Delivery
For cTACE: a mixture of chemotherapy (doxorubicin/cisplatin) emulsified in Lipiodol oil is injected, followed by gelfoam or microsphere embolic material. For DEB-TACE: drug-eluting beads pre-loaded with doxorubicin are injected β simultaneously releasing drug and blocking the vessel.
- 6
Post-Procedure Arteriogram
A final arteriogram confirms stasis (blood flow arrest) in the target vessel and that drug/embolic delivery is complete. The catheter is removed and pressure is applied to the puncture site for 10β15 minutes.
TACE Indications: When It Is Used
TACE has established roles across several liver cancer indications β from curative-intent bridging to palliative locoregional control.
| Indication | TACE Role | Alternative / Combination | Evidence Strength |
|---|---|---|---|
| HCC β BCLC B (intermediate stage) | Standard of care β first-line locoregional treatment | Sorafenib / lenvatinib for systemic progression; Y-90 radioembolisation | Level 1 β two RCTs (Llovet et al., Lo et al.) demonstrated OS benefit vs best supportive care |
| HCC β bridge to liver transplant (BCLC A within Milan criteria) | Prevents dropout by controlling disease during waiting list period | Ablation (RFA/cryoablation) for lesions β€3 cm; TACE preferred for multiple lesions | Retrospective and prospective series; widely adopted as standard |
| HCC β downstaging beyond Milan criteria to transplant eligibility | Reduces tumour burden to within Milan criteria β allows relisting | Y-90 for better depth control; combination TACE + ablation | Registry and institutional series; UNOS downstaging protocol |
| Colorectal liver metastases (CRLM) | Palliative or combined with systemic therapy in refractory disease | DEBIRI-TACE (irinotecan DEB) β Phase III EPOCH trial; FOLFOX + bevacizumab | EPOCH trial: DEBIRI + FOLFOX vs FOLFOX alone; modest OS benefit in 2nd+ line |
| Cholangiocarcinoma (intrahepatic) | Palliative disease control in selected cases | Systemic gemcitabine + cisplatin; Y-90 for hilar disease | Limited β Phase II series; not guideline-standard but used at specialist centres |
| Hepatic metastases from NET | Locoregional control of symptomatic hepatic metastases | PRRT (lutetium-177 DOTATATE) for SSTR+ NET; somatostatin analogues | Randomised and observational data; widely used in carcinoid syndrome |
Benefits vs Limitations of TACE
TACE is a highly effective locoregional treatment for selected patients β but its success depends on adequate liver function reserves and appropriate patient selection.
Benefits
- No surgery, no general anaesthesia for most patientsTACE is a catheter-based procedure under conscious sedation β recovery is significantly faster than any surgical liver resection.
- Repeatable β multiple sessions possible over yearsUnlike surgical resection (limited by functional liver remnant) or ablation (size constraints), TACE can be repeated as needed across the treatment course.
- Preserves liver parenchymaTargeted delivery to the tumour's feeding vessels spares surrounding liver β crucial in cirrhotic patients where liver reserve is limited.
- Effective bridge to transplant and downstagingThe most commonly used strategy to keep patients within Milan criteria during transplant waiting periods β preventing disease progression from causing transplant disqualification.
Limitations
- Requires adequate liver function β Child-Pugh A/B7Child-Pugh C cirrhosis is a contraindication β TACE-induced liver injury in severely decompensated disease can precipitate fatal liver failure.
- Post-embolisation syndrome: fever, pain, nauseaAlmost universal in the first 24β72 hours post-TACE β requires hospitalisation, antiemetics, analgesics, and hydration for 1β3 days.
- Not curative for large or multifocal diseaseTACE provides locoregional disease control but does not eliminate systemic micro-metastatic disease β systemic therapy is required alongside TACE in many patients.
- Biliary injury risk with central lesionsLesions close to the main biliary ducts carry risk of chemobiliary fistula or biloma β DEB-TACE may be slightly safer than cTACE near central ducts.
TACE: Key Clinical Numbers
Reference figures from pivotal trials and contemporary series.
- 2β3 yrMedian OS improvement with TACE vs best supportive care in BCLC B HCCTwo RCTs (Llovet 2002, Lo 2002) demonstrated median OS of 24β26 months with TACE vs 16β18 months with best supportive care β establishing TACE as the BCLC B standard.
- 70β80%Objective response rate (RECIST) in Child-Pugh A HCC after TACEModern superselective DEB-TACE and cTACE achieve high response rates in selected patients β though response does not always translate to OS benefit.
- 1β2 daysTypical post-TACE hospital stay for uncomplicated proceduresMost patients are admitted overnight for monitoring and post-embolisation syndrome management; complex or high-volume TACE may require longer observation.
- 4β8 wksStandard interval between TACE sessionsMost TACE protocols schedule repeat sessions at 4β8 weekly intervals based on imaging response β 'on-demand' TACE guided by MRI response is increasingly preferred.
More from the TACE Resource Library
Continue exploring TACE β from technique selection to patient eligibility, clinical evidence, and access.
- TACE Therapy β Complete Treatment Guide
- cTACE vs DEB-TACE: Which Technique Is Right for Your HCC?
- TACE Patient Selection: BCLC Staging and Child-Pugh Score
- TACE Survival Data: Evidence from Pivotal Clinical Trials
- TACE as Bridge to Liver Transplant: How It Works
- TACE for Colorectal Liver Metastases (DEBIRI)
Frequently Asked Questions
Common questions from patients and families encountering TACE for the first time.
Understanding TACE
Will I be asleep during the TACE procedure?
Most TACE procedures are performed under conscious sedation β you receive IV sedation (typically midazolam and fentanyl) that makes you drowsy and relaxed but not fully unconscious. You will feel pressure in the groin but should not feel sharp pain. Some centres use general anaesthesia, particularly for complex or prolonged procedures. If you are anxious about being aware during the procedure, discuss sedation preferences with your interventional radiologist beforehand β deeper sedation can usually be arranged.
How will I feel after TACE and how long does recovery take?
Post-embolisation syndrome β fever (38β39Β°C), right upper quadrant pain or aching, nausea, and fatigue β is expected in the 24β72 hours after TACE and occurs in the majority of patients. It reflects the inflammatory response to tumour ischaemia and is managed with paracetamol, anti-emetics, and IV fluids during a 1β3 day hospital stay. Most patients feel significantly better by Day 3β5. Full energy recovery takes 1β2 weeks. You will not be able to drive on the day of the procedure due to sedation.
Does TACE cure liver cancer?
TACE is not considered a curative treatment for most patients with HCC β it provides locoregional disease control, slows progression, extends survival, and serves as a bridge to transplantation for selected patients. Complete pathological necrosis of the target tumour does occur in some cases β particularly with small, well-vascularised HCC treated with superselective TACE β but residual viable tumour and new lesion formation mean that most patients require multiple sessions and ongoing surveillance. The goal of TACE is typically disease control and survival prolongation rather than cure, except in the transplant bridge setting.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is TACE Right for Your Liver Cancer?
CancerFax reviews your imaging, Child-Pugh score, BCLC stage, and prior treatment history to assess whether TACE is appropriate β and connects you with specialist interventional radiologists at high-volume liver cancer centres in China and India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.